United States, Nevada, Las Vegas, DelveInsight’s ‘Severe Hypertriglyceridemia Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Severe Hypertriglyceridemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Severe Hypertriglyceridemia pipeline domain.
Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report
Severe Hypertriglyceridemia Overview
Hypertriglyceridemia is a common condition, which is defined as having a high level (above 150 mg/dL) of triglycerides, a type of fat, in the bloodstream. Hypertriglyceridemia can lead to conditions including atherosclerosis (hardening of the arteries), obesity, and insulin resistance, which all can contribute to increased risk of cardiovascular disease (CVD). More than 2.1 million adults in the United States have severe hypertriglyceridemia (SHTG), defined as having a triglyceride level over 500 mg/dL. In addition to increasing the risk of CVD, SHTG is also a known risk factor for acute pancreatitis, a life-threatening condition. Risk factors for SHTG can include genetic disorders, obesity, untreated diabetes, and certain medications. While SHTG often causes no noticeable symptoms, individuals with extremely high levels of triglycerides (greater than 2,000 mg/dL) can experience recurrent abdominal pain, nausea, vomiting, xanthomas (yellow-colored bumps on the skin), and acute pancreatitis. There are many ways to prevent and treat SHTG. Lifestyle changes impacting SHTG include lowering fat and carbohydrate intake, reducing alcohol consumption, and quitting smoking. For some people, lifestyle changes aren’t enough to reduce triglycerides to the appropriate levels, leaving them at risk for additional complications. In these cases, there are pharmacological therapies that can reduce triglyceride levels to healthier levels
Severe Hypertriglyceridemia Pipeline Analysis: Drug Profile
ARO-APOC3: Arrowhead Pharmaceuticals
ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Currently, it is in Phase II stage of clinical trial evaluation to treat Severe Hypertriglyceridemia.
Discover more about the emerging Severe Hypertriglyceridemia drugs @ Severe Hypertriglyceridemia Treatment Drugs
Severe Hypertriglyceridemia Key Companies
Severe Hypertriglyceridemia Pipeline Therapies
Severe Hypertriglyceridemia Pipeline Therapeutics Assessment
Scope of the Severe Hypertriglyceridemia Pipeline Report
Find out more about the Severe Hypertriglyceridemia treatment options in development @ Severe Hypertriglyceridemia Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report to know more about the leading companies in the Severe Hypertriglyceridemia pipeline domain.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/